Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Determine if elevation in NLR associates with greater weight loss, cachexia and lower vitamin D concentrations in advanced cancer patients

Source: Associations between NLR symptoms and toxicities. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Associations between inflammatory biomarkers, symptoms, treatment toxicities and quality of life in people with advanced cancer receiving systemic anti-cancer treatments: a systematic review

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Associations between inflammatory biomarkers, symptoms, treatment toxicities and quality of life in people with advanced cancer receiving systemic anti-cancer treatments: a systematic review

Systematic review · Supportive Care in Cancer · 2026

Original publication title

Associations between inflammatory biomarkers, symptoms, treatment toxicities and quality of life in people with advanced cancer receiving systemic anti-cancer treatments: a systematic review

Helen Andersen; Wei-Hong Liu; Patsy Yates; Morgan J. Farley; Kim E. Alexander

© Crown 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Further research is needed to establish specific cut-off values of NLR to increase the utility of this biomarker in clinical practice. PLR and MLR warrant further investigation for association with symptoms, treatment toxicities and QoL.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Examine the quality of evidence relating to the association of routine inflammatory biomarkers neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) with symptoms, treatment toxicities, and quality of life (QoL) in people with advanced cancer.

Source: Purpose

Abstract: What methods does the paper describe?

Searches were conducted in MEDLINE, Embase, CINAHL and the Cochrane database to identify studies that investigated associations between NLR, PLR and MLR with symptoms, toxicities and QoL in people with advanced cancer. The evidence was graded as good, fair or poor through the application of the National Institute of Health (NIH) quality assessment tool. A narrative approach was used for data synthesis.

Source: Methods

Abstract: Results

Of the 38 studies reviewed, NLR was the most frequently investigated biomarker. Thirteen studies found no association between NLR and symptoms or treatment toxicities. Of the 25 that did, five provided good quality evidence linking NLR to immune-related adverse events (irAEs), chemotherapy-related haematological toxicities and insufficient oral intake. However, NLR cut-off values varied across studies. Ten studies reported an association between PLR and symptoms or treatment toxicities whilst six studies found no associations; one study found no association with MLR and symptoms or treatment toxicities.

Source: Results

Abstract: Conclusion

Further research is needed to establish specific cut-off values of NLR to increase the utility of this biomarker in clinical practice. PLR and MLR warrant further investigation for association with symptoms, treatment toxicities and QoL.

Source: Conclusion
Authors’ abstract

Purpose

Examine the quality of evidence relating to the association of routine inflammatory biomarkers neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) with symptoms, treatment toxicities, and quality of life (QoL) in people with advanced cancer.

Methods

Searches were conducted in MEDLINE, Embase, CINAHL and the Cochrane database to identify studies that investigated associations between NLR, PLR and MLR with symptoms, toxicities and QoL in people with advanced cancer. The evidence was graded as good, fair or poor through the application of the National Institute of Health (NIH) quality assessment tool. A narrative approach was used for data synthesis.

Results

Of the 38 studies reviewed, NLR was the most frequently investigated biomarker. Thirteen studies found no association between NLR and symptoms or treatment toxicities. Of the 25 that did, five provided good quality evidence linking NLR to immune-related adverse events (irAEs), chemotherapy-related haematological toxicities and insufficient oral intake. However, NLR cut-off values varied across studies. Ten studies reported an association between PLR and symptoms or treatment toxicities whilst six studies found no associations; one study found no association with MLR and symptoms or treatment toxicities.

Conclusion

Further research is needed to establish specific cut-off values of NLR to increase the utility of this biomarker in clinical practice. PLR and MLR warrant further investigation for association with symptoms, treatment toxicities and QoL.

Publication and source details

Original title: Associations between inflammatory biomarkers, symptoms, treatment toxicities and quality of life in people with advanced cancer receiving systemic anti-cancer treatments: a systematic review

Helen Andersen; Wei-Hong Liu; Patsy Yates; Morgan J. Farley; Kim E. Alexander

Supportive Care in Cancer · 2026

© Crown 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Queensland University of Technology

Open Access funding enabled and organized by CAUL and its Member Institutions

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:12:39.955684+00:00

DOI: 10.1007/s00520-026-10922-5 · PMC13319193